Loading...
Loading...
This is your Benzinga news summary and traders' outlook for Tuesday, September 13, 2011, covering headlines from overnight and Tuesday's pre-market session.
Today in domestic pre-market trading, U.S equity futures are trading lower. At last check, Dow futures are slightly lower by about 55 points or (0.5%) and the U.S. dollar trades lower near the $77.57 level.
Earlier this morning, Brean Murray upgraded MGM
MGM to Buy and Citigroup upgraded Kansas City Southern
KSU to Buy as well. View all of
today's upgrades here.
Morgan Stanley downgraded SolarWinds
SWI to Underweight and Jefferies downgraded NetLogic
NETL to Hold. View all of
today's downgrades here.
Goldman Sachs removed Lockheed Martin
LMT from its Americas Sell List and Sterne Agee lowered United Technologies'
UTX price target to $95 from $101. View all other
of today's analyst ratings here.
Overseas, European markets are mixed in afternoon trading. Britain's FTSE 100 lost 0.6%, Germany's DAX added 0.2% and France's CAC 40 slid 1% on the session. Asian stocks ended the session mixed as well. China's Shanghai Index lost 1%, Japan's Nikkei 225 added 1%, and Hong Kong's Hang Seng Index tumbled 4.2%.
On the economic calendar, the NFIB Small Business Optimism Index came in at 88.1 versus an 88 estimate. The Import Price Index is set to be reported at 8:30 a.m., IBD/TIPP Economic Optimism Index is due at 10:00 a.m., and the monthly budget statement is to be reported at 2:00 p.m.
On the commodity front,
gold and
silver futures are slightly higher in pre-market trading, with gold trading higher by about 0.15%. Energy futures are higher as well with
crude oil up over the $89.00 level and
gasoline futures are trading higher by about 0.4%.
Natural Gas futures are unchanged and
copper futures are trading slightly lower this morning.
On the earnings front, Cracker Barrel
CBRL reported Q4 EPS of $1.00 on revenues of $612.9 million; The Street was looking for $0.96 per share on revenues of $623.4 million. The company also guided fiscal 2012 revenue at $2.55-$2.6 billion versus analyst estimates of $2.53 billion
In corporate news, VIVUS , Inc.
VVUS today presented
positive results from the avanafil phase 3 study in diabetics.
This concludes your news summary for September 13, 2011.
Want to receive the morning news summary to you inbox every morning? Click
here to subscribe now.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Posted In: EarningsLong IdeasNewsGuidanceShort IdeasUpgradesDowngradesFuturesPrice TargetCommoditiesForexFDAEventsGlobalEcon #sEconomicsPre-Market OutlookMarketsAnalyst RatingsTrading IdeasGeneral
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in